ADD ANI AS A TRUSTED SOURCE
googleads
ANI Logo
Menu
Business

Aurobindo Pharma receives FDA nod for rosuvastatin calcium tabs

New Delhi, July 20 (ANI): Leading Indian pharmaceutical company Aurobindo Pharma has announced receiving the final approval from the US health regulator USFDA for rosuvastatin calcium tablets, used in lowering cholesterol.

ANI Jul 20, 2016 19:10 IST googleads

Aurobindo Pharma receives FDA nod for rosuvastatin calcium tabs
New Delhi, July 20 (ANI): Leading Indian pharmaceutical company Aurobindo Pharma has announced receiving the final approval from the US health regulator USFDA for rosuvastatin calcium tablets, used in lowering cholesterol. In a BSE filing, the company said that it has finally got a nod by the US Food and Drug Administration (USFDA) for rosuvastatin calcium tablets. "Aurobindo was one of the first applicants to submit a substantially complete ANDA with a paragraph IV certification and hence, it is eligible for 180 days of generic drug shared exclusivity," it further added. Rosuvastatin calcium tablets are generic version of Crestor tablets of IPR Pharmaceuticals, Inc., and the approval has been granted in the strength of five mg, 10 mg, 20 mg and 40 mg. Crestor is used to lower cholesterol and fats (triglycerides) in the blood and is used to reduce the chances of developing problems such as heart disease and strokes. Presently, Aurobindo Pharma holds a total of 274 ANDA approvals (234 final approvals including 13 from Aurolife Pharma LLC and 40 tentative approvals) from the US. The stock of Aurobindo Pharma was seen trading 3.87 percent higher at Rs. 788.65 on the BSE after approval. (ANI)

Get the App

What to Read Next

Business

U.S.–India Tariff Reduction Deal Creates Momentum for Harsoria

U.S.–India Tariff Reduction Deal Creates Momentum for Harsoria

New Delhi [India], March 11: Together as Medsoria, the joint venture will increase production capabilities with a new 70,000 square feet (6,500 square meters) U.S. FDA-compliant facility and engender future collaboration on developing new product lines. With the recent reporting of a trade deal between the India and U.S. to reduce tariffs and promote improved trade relations between the two countries, the joint venture could not arrive at a better time.

Read More
Business

Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025

Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025

Mumbai (Maharashtra) [India], March 6: Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced its recognition among the top 1% of companies worldwide in the S&P Global Corporate Sustainability Assessment (CSA). Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally, and the leader across all sectors in India, surpassing both Indian and international peers.

Read More
Business

IT, oil show caution amid AI disruptions, West Asia conflict

IT, oil show caution amid AI disruptions, West Asia conflict

The IT services sector is facing challenges due to Artificial Intelligence (AI), with investors expressing concerns about job losses and the transition period. However, other sectors like real estate, autos, and domestic pharma companies showed more positive outlooks, with some showing steady growth, according to Pratik Gupta, CEO and Co- Head of Kotak Institutional Equities. Gupta expressed his views on the Indian economy and market outlook at a press conference on Kotak Securities Outlook held today in Mumbai.

Read More
Business

Stock market ends flat, Nifty falls below 25,500 level  

Stock market ends flat, Nifty falls below 25,500 level  

The Sensex closed at 82,276.07, up 50 points, while the Nifty 50 closed 58 points higher at 25,482.50. Among the key sectors, on the gaining end, were auto, healthcare, IT, metal, while telecom, FMCG, oil & gas, and PSU Bank faced losses.

Read More
Business

Healing Pharma Strengthens Its Lifesaving Mission

Healing Pharma Strengthens Its Lifesaving Mission

Mumbai (Maharashtra) [India], February 25: Reinforcing its commitment to saving lives beyond medicines, Healing Pharma India Private Limited (HPIPL) successfully carried out its second CSR initiative in Maharashtra by donating a fully equipped ambulance to Jeevanam Hospital & Research Centre LLP in Mumbai. Following its recent contribution in Pune, the company continues to take meaningful steps toward strengthening emergency healthcare accessibility where it needs most.

Read More
Business

Morepen Bags Rs. 825 Crore Global Deal

Morepen Bags Rs. 825 Crore Global Deal

Gurugram (Haryana) [India], February 23: Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs. 825 crore (USD 91 million) from a leading global pharma major.

Read More
Business

India healthcare sector growth to strengthen over next 3 years

India healthcare sector growth to strengthen over next 3 years

The domestic healthcare sector is expected to see stronger growth over the next three years supported by new drug launches, while earnings from the US generics business are likely to remain flat for most companies, according to a report by Systematix Research.

Read More
Business

Sai Life Sciences to Recruit 700+ Professionals in FY27

Sai Life Sciences to Recruit 700+ Professionals in FY27

Hyderabad (Telangana) [India], February 20: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India's leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026-27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services.

Read More
Business

India’s medical devices industry to reach USD 50.1 billion

India’s medical devices industry to reach USD 50.1 billion

According to the report, growth is being propelled by government initiatives such as National Medical Devices Policy (NMDP), Production-Linked Incentive (PLI) Scheme, Scheme for Promotion of Medical Devices Parks, and MedTech Mitra. The study assumes greater significance in the light of the Union Budget-FY27's renewed focus on bio-pharma research in the country.

Read More
Business

XLRI Records Strong Final Placements for PGDM (BM) & PGDM (HRM)

XLRI Records Strong Final Placements for PGDM (BM) & PGDM (HRM)

New Delhi [India], February 11: XLRI Jamshedpur and XLRI Delhi-NCR completed the Final Recruitment Process for the graduating class of 2024-26, which is an additional milestone for their two-year PGDM (BM) and PGDM (HRM) programmes. The final recruitment process was part of a larger initiative to place the 576 students from both campuses with 145 different recruiting organisations, including 25 organisations that partnered with XLRI for the first time. The strong calibre of the cohort was evident in the fact that recruiters made over 576 domestic offers and 2 international offers during the recruitment process. The results of summer internships were reflected in the fact that 42.5% of students in the cohort received Pre-Placement Offers (PPOs), demonstrating the industry's high regard for students' professional capabilities.

Read More
Home About Us Our Products Advertise Contact Us Terms & Condition Privacy Policy

Copyright © aninews.in | All Rights Reserved.